The Peak District became the UK’s first national park on 17 April 1951; albeit the National Trust owns a 12% minority. Geographically, it forms the southern end of the Pennines
Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways
ValiRx Plc (LON:VAL) is a clinical-stage bio-pharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are
Morses Club Plc (LON:MCL) having completed a major integration, and a good FY17 management can focus on carefully controlled growth. In the Home Collect (HCC) business, management reports the expected
Alliance Pharma Plc (LON:APH) buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma
Chamberlin Plc (LON:CMH) is on track both strategically and operationally following its recent re-positioning move. The Group is developing its product offering to the automobile turbocharger industry through expansion of
Fulham Shore Plc (LON:FUL) proven management team is expanding both its main brands, Franco Manca and The Real Greek, ahead of expectations. FY17 saw a 55% rise in restaurants open,
Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have
PPHE Hotel Group Ltd (LON:PPH) Q1 trading statement indicates a much stronger than anticipated performance, with LFL revenues up 17%, in spite of Easter falling in Q2 2017 (Q1 2016).
Abzena plc (LON:ABZA) is an integrated group offering a broad range of services and technologies to improve the chances of discovering and developing effective biopharmaceutical drugs. With strong footprints in
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
